WO2007077505A3 - Crystalline l-menthyl (2r, 5s)-5-(4-amino-5-fluoro-2-oxo-2h-pyrimidin-1-yl)[1, 3]oxathiolan-2-carboxylate and process for preparation thereof - Google Patents

Crystalline l-menthyl (2r, 5s)-5-(4-amino-5-fluoro-2-oxo-2h-pyrimidin-1-yl)[1, 3]oxathiolan-2-carboxylate and process for preparation thereof Download PDF

Info

Publication number
WO2007077505A3
WO2007077505A3 PCT/IB2006/054981 IB2006054981W WO2007077505A3 WO 2007077505 A3 WO2007077505 A3 WO 2007077505A3 IB 2006054981 W IB2006054981 W IB 2006054981W WO 2007077505 A3 WO2007077505 A3 WO 2007077505A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxathiolan
menthyl
pyrimidin
carboxylate
oxo
Prior art date
Application number
PCT/IB2006/054981
Other languages
French (fr)
Other versions
WO2007077505A2 (en
Inventor
Santosh Richhariya
Kaptan Singh
Mohan Prasad
Original Assignee
Ranbaxy Lab Ltd
Santosh Richhariya
Kaptan Singh
Mohan Prasad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd, Santosh Richhariya, Kaptan Singh, Mohan Prasad filed Critical Ranbaxy Lab Ltd
Publication of WO2007077505A2 publication Critical patent/WO2007077505A2/en
Publication of WO2007077505A3 publication Critical patent/WO2007077505A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Provided herein is crystalline L-menthyl (2R, 5S)-5-(4-amino-5-fluoro-2-oxo-2H- pyrimidin-l-yl)[l,3]oxathiolan-2-carboxylate and a process for preparation thereof.
PCT/IB2006/054981 2005-12-30 2006-12-20 Crystalline l-menthyl (2r, 5s)-5-(4-amino-5-fluoro-2-oxo-2h-pyrimidin-1-yl)[1, 3]oxathiolan-2-carboxylate and process for preparation thereof WO2007077505A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3518DE2005 2005-12-30
IN3518/DEL/2005 2005-12-30

Publications (2)

Publication Number Publication Date
WO2007077505A2 WO2007077505A2 (en) 2007-07-12
WO2007077505A3 true WO2007077505A3 (en) 2007-10-11

Family

ID=38093024

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/054981 WO2007077505A2 (en) 2005-12-30 2006-12-20 Crystalline l-menthyl (2r, 5s)-5-(4-amino-5-fluoro-2-oxo-2h-pyrimidin-1-yl)[1, 3]oxathiolan-2-carboxylate and process for preparation thereof

Country Status (1)

Country Link
WO (1) WO2007077505A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009005338A2 (en) * 2007-07-05 2009-01-08 Ultimorphix Technologies B.V. Solid forms ult-i, ult-2 and ult-3 of emtricitabine
EP2562162B1 (en) 2008-01-22 2015-08-19 Dow AgroSciences LLC N-cyano-4-amino-5-fluoro-pyrimidine derivatives as fungicides
AU2011222471B2 (en) * 2010-03-04 2014-07-31 Sun Pharmaceutical Industries Limited A process for stereoselective synthesis of 5-fluoro-1-(2R,5S)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
EP2377862A1 (en) 2010-03-29 2011-10-19 Esteve Química, S.A. Process for obtaining emtricitabine
WO2014174532A2 (en) * 2013-04-26 2014-10-30 Laurus Labs Private Limited An improved process for the preparation of emtricitabine
CN106146481A (en) * 2015-04-07 2016-11-23 江苏普信制药有限公司 A kind of preparation method of nucleoside analog
CN106187988A (en) * 2016-07-28 2016-12-07 厦门市蔚嘉化学科技有限公司 A kind of new technology preparing emtricitabine intermediate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0515157A1 (en) * 1991-05-21 1992-11-25 Biochem Pharma Inc. Processes for the diastereoselective synthesis of nucleosides
WO1993003027A1 (en) * 1991-08-01 1993-02-18 Biochem Pharma Inc. 1,3-oxathiolane nucleoside analogues
WO2004085432A1 (en) * 2003-03-24 2004-10-07 Clariant Life Science Molecules (Italia) Spa Process and intermediates for preparing emtricitabine
CN1563002A (en) * 2004-03-17 2005-01-12 济南久创化学有限责任公司 Suitqable to industrialized method for preparing emtricitabine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0515157A1 (en) * 1991-05-21 1992-11-25 Biochem Pharma Inc. Processes for the diastereoselective synthesis of nucleosides
WO1993003027A1 (en) * 1991-08-01 1993-02-18 Biochem Pharma Inc. 1,3-oxathiolane nucleoside analogues
WO2004085432A1 (en) * 2003-03-24 2004-10-07 Clariant Life Science Molecules (Italia) Spa Process and intermediates for preparing emtricitabine
CN1563002A (en) * 2004-03-17 2005-01-12 济南久创化学有限责任公司 Suitqable to industrialized method for preparing emtricitabine

Also Published As

Publication number Publication date
WO2007077505A2 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
USD537223S1 (en) Garbage can
USD538995S1 (en) Garbage can
USD538000S1 (en) Garbage can
USD580059S1 (en) Fastening device for dental prostheses
USD566001S1 (en) Reef artifact
WO2007077505A3 (en) Crystalline l-menthyl (2r, 5s)-5-(4-amino-5-fluoro-2-oxo-2h-pyrimidin-1-yl)[1, 3]oxathiolan-2-carboxylate and process for preparation thereof
CA2560252A1 (en) Process for the production of atorvastatin calcium in amorphous form
WO2009036281A3 (en) Bortezomib and process for producing same
WO2006127941A3 (en) Amorphous cinacalcet hydrochloride and preparation thereof
ZA200309709B (en) Solid crystalline IM-9, and a process for its preparation.
WO2006081515A3 (en) Duloxetine hydrochloride polymorphs
USD543357S1 (en) Carry case
WO2004035800A3 (en) Intermediate cefdinir salts
IL181766A0 (en) A process for the preparation of [1,4,5]-oxadiazepine derivatives
USD538513S1 (en) Hat having self band with bound edge
USD583590S1 (en) Table
USD538500S1 (en) Garbage can
USD540983S1 (en) Hair clip
USD647611S1 (en) Tampon
USD542705S1 (en) Holding device
USD532430S1 (en) Mitre saw
WO2007144699A3 (en) Process for the preparation of alfuzosin
WO2007022488A3 (en) Crystalline rosuvastatin intermediate
AU2002344514A1 (en) A natural compound useful for treating diabetes, its preparation and use
USD551948S1 (en) Reel

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06842637

Country of ref document: EP

Kind code of ref document: A2